Location History:
- New York, NY (US) (2003 - 2023)
- Bronx, NY (US) (2004 - 2023)
Company Filing History:
9 out of 512 
3 out of 559 
3 out of 832,843 Years Active: 2003-2025
Title: Michael R McDevitt: Innovator in Cancer Treatment
Introduction
Michael R McDevitt, based in Bronx, NY, is a notable inventor with a significant contribution to the field of cancer treatment. With a portfolio of 14 patents, he has been at the forefront of developing innovative methods and compositions aimed at improving therapeutic options for neoplastic diseases.
Latest Patents
Among his latest inventions is a groundbreaking method for the one-step labeling of antibodies to achieve high specific activity with actinium-225. This innovative approach enables the chelation of actinium-225 to a biomolecule, such as an antibody, utilizing a bifunctional ligand in a 3-arm configuration. The method enhances the radiochemical yield of actinium-225 complexes and is performed at physiological temperatures. Moreover, McDevitt’s patents also cover the development of high specific activity actinium-225 complexes and their pharmaceutical applications for treating various cancer disorders.
Another significant patent is focused on DOTA-hapten compositions intended for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy. These compositions incorporate novel DOTA-haptens that can be complexed with radioisotopes, enabling improved diagnostic imaging and therapeutic efficacy in cancer treatment.
Career Highlights
Throughout his career, Michael R McDevitt has worked at prestigious institutions such as the Sloan-Kettering Institute for Cancer Research. His work has significantly advanced the field of radiopharmaceuticals, contributing valuable insights into cancer therapy.
Collaborations
In his innovative journey, McDevitt has collaborated with esteemed colleagues, notably David A Scheinberg and Dangshe Ma. These partnerships have been instrumental in pushing the boundaries of existing cancer treatment methodologies and enhancing research efforts.
Conclusion
Michael R McDevitt’s contributions to the scientific community through his 14 patents reflect his dedication to finding innovative solutions in cancer treatment. His latest work on actinium-225 complexes and DOTA-hapten compositions stands as a testament to his ongoing commitment to improving therapeutic outcomes for patients battling neoplastic diseases. Pioneering advancements such as these not only showcase McDevitt's expertise but also highlight the crucial role of inventors in the development of life-saving medical technologies.